This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
B of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68
BofA Securities Upgrades PTC Therapeutics(PTCT.US) to Buy Rating, Raises Target Price to $68
PTC Therapeutics Is Maintained at Equal-Weight by Barclays
Baird Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $66
Barclays Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Cuts Target Price to $42
J.P. Morgan Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Cuts Target Price to $67
PTC Therapeutics' Earnings Call: Strong Start to 2025
Express News | Baird Maintains Outperform on PTC Therapeutics, Lowers Price Target to $66
Express News | RBC Capital Maintains Outperform on PTC Therapeutics, Raises Price Target to $58
PTC Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results and Raised Its FY25 Sales Guidance. Also, Citigroup Upgraded Its Price Target on the Stock From Sell to Neutral.
Express News | PTC Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results and Raised Its FY25 Sales Guidance. Also, Citigroup Upgraded Its Price Target on the Stock From Sell to Neutral
PTC Therapeutics Price Target Cut to $67.00/Share From $75.00 by JP Morgan
PTC Therapeutics Is Maintained at Overweight by JP Morgan
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Citigroup Upgrades PTC Therapeutics to Neutral, Lowers Price Target to $40
PTC Therapeutics Analyst Ratings
Citi Upgrades PTC Therapeutics(PTCT.US) to Hold Rating, Cuts Target Price to $40
PTC Therapeutics Swings to Q1 Earnings, Revenue Increases